Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 38Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 10Neoplasm Metastasis 7Hodgkin Disease 6Recurrence 4Neoplasms 4Uterine Cervical Neoplasms 3Sarcoma 2Rhabdomyosarcoma 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Carcinoma 2Breast Neoplasms, Male 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Pleural Effusion, Malignant 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non - Small Cell Lung Cancer NSCLC 1Neuroendocrine Tumors 1Neuralgia 1Metatropic dwarfism 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Locally Advanced Non-Small Cell Lung Cancer 1Lethal Congenital Contracture Syndrome 2 1Glioma 1

Interventions

temsirolimus 1ganitumab 1efineptakin alfa 1Vinorelbine 1Vincristine 1Sirolimus 1Receptor Protein-Tyrosine Kinases 1Radiotherapy 1Radiation 1Irinotecan 1Dasatinib 1Dactinomycin 1Cyclophosphamide 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma, Alveolar × Vinorelbine × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡